Skip to content

Study · Randomized controlled trial · n = 21 · 2009

6 results

Randomized, double-blind, pilot evaluation of intravenous glutathione in Parkinson's disease.

Hauser RA, Lyons KE, McClain T, Carter S, Perlmutter D

Movement disorders : official journal of the Movement Disorder Society1 May 2009Cited by 88 (Europe PMC)

PMID19230029 (opens in a new tab)DOI10.1002/mds.22401 (opens in a new tab)PepBankPUB-19230029
Publisher pagePubMedAsk about this study
Jump to 6 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study6

6 results from studies that gave the peptide. 6 results from people.

  1. 01HumanRandomized controlled trialSafety outcome

    In Parkinson's disease, neither glutathione nor placebo caused withdrawals because of adverse events.

    In plain wordsIn Parkinson's disease, no participants withdrew because of adverse events in either the glutathione or placebo group.

    Peptide
    Glutathione
    Outcome
    No significant changeWithdrawals because of adverse events
    Study

    n = 21

    Comparator
    Placebo
    Outcome group
    Adverse events · Nervous system and cognition
    Studied dose
    1,400 mg three times a week · intravenous · 4 weeksAs given in this study (human).

    Source sentences

    Summary
    Glutathione was well tolerated and there were no withdrawals because of adverse events in either group.
    2 context sentences
    Summary · context
    This was a randomized, placebo-controlled, double-blind, pilot trial in subjects with PD whose motor symptoms were not adequately controlled with their current medication regimen.
    Summary · context
    Subjects were randomly assigned to receive intravenous glutathione 1,400 mg or placebo administered three times a week for 4 weeks.
  2. 02HumanRandomized controlled trialSafety outcome

    In Parkinson's disease, reported adverse events were similar with glutathione and placebo.

    In plain wordsIn Parkinson's disease, reported adverse events were similar with glutathione and placebo.

    Peptide
    Glutathione
    Outcome
    No significant changeReported adverse events
    Study

    n = 21

    Comparator
    Placebo
    Outcome group
    Adverse events · Nervous system and cognition
    Studied dose
    1,400 mg three times a week · intravenous · 4 weeksAs given in this study (human).

    Source sentences

    Summary
    Reported adverse events were similar in the two groups.
    2 context sentences
    Summary · context
    This was a randomized, placebo-controlled, double-blind, pilot trial in subjects with PD whose motor symptoms were not adequately controlled with their current medication regimen.
    Summary · context
    Subjects were randomly assigned to receive intravenous glutathione 1,400 mg or placebo administered three times a week for 4 weeks.
  3. 03HumanRandomized controlled trialSafety outcome

    In Parkinson's disease, intravenous glutathione was well tolerated.

    In plain wordsIn Parkinson's disease, intravenous glutathione was well tolerated.

    Peptide
    Glutathione
    Outcome
    Not applicableTolerability
    Study

    n = 11

    Outcome group
    Adverse events · Nervous system and cognition
    Studied dose
    1,400 mg three times a week · intravenous · 4 weeksAs given in this study (human).

    Source sentences

    Summary
    Glutathione was well tolerated and there were no withdrawals because of adverse events in either group.
    2 context sentences
    Summary · context
    This was a randomized, placebo-controlled, double-blind, pilot trial in subjects with PD whose motor symptoms were not adequately controlled with their current medication regimen.
    Summary · context
    Subjects were randomly assigned to receive intravenous glutathione 1,400 mg or placebo administered three times a week for 4 weeks.
  4. 04HumanRandomized controlled trialEfficacy outcome

    In Parkinson's disease, glutathione did not significantly change UPDRS scores compared with placebo.

    In plain wordsIn Parkinson's disease, glutathione did not significantly change disease rating scores compared with placebo.

    Peptide
    Glutathione
    Outcome
    No significant changeUPDRS score changes
    Study

    n: not reported in source

    Comparator
    Placebo
    Outcome group
    Exercise and physical function · Nervous system and cognition
    Studied dose
    1,400 mg three times a week · intravenous · 4 weeksAs given in this study (human).

    Source sentences

    Summary
    There were no significant differences in changes in Unified Parkinson's Disease Rating Scale (UPDRS) scores.
    2 context sentences
    Summary · context
    This was a randomized, placebo-controlled, double-blind, pilot trial in subjects with PD whose motor symptoms were not adequately controlled with their current medication regimen.
    Summary · context
    Subjects were randomly assigned to receive intravenous glutathione 1,400 mg or placebo administered three times a week for 4 weeks.
  5. 05HumanRandomized controlled trialEfficacy outcome

    In Parkinson's disease, UPDRS ADL and motor improvement favored glutathione by 2.8 units versus placebo, without statistical significance.

    In plain wordsIn Parkinson's disease, glutathione improved daily activity and motor scores 2.8 units more than placebo, without statistical significance.

    Peptide
    Glutathione
    Outcome
    No significant changeUPDRS ADL and motor during treatment
    Study

    n: not reported in source

    Comparator
    Placebo
    Outcome group
    Exercise and physical function · Nervous system and cognition
    Studied dose
    1,400 mg three times a week · intravenous · 4 weeksAs given in this study (human).

    Measurements

    UPDRS ADL + motor improvement difference
    2.8 units
    glutathione versus placebo during treatment
    P value
    0.32
    during treatment

    Source sentences

    Summary
    Over the 4 weeks of study medication administration, UPDRS ADL + motor scores improved by a mean of 2.8 units more in the glutathione group (P = 0.32)
    2 context sentences
    Summary · context
    This was a randomized, placebo-controlled, double-blind, pilot trial in subjects with PD whose motor symptoms were not adequately controlled with their current medication regimen.
    Summary · context
    Subjects were randomly assigned to receive intravenous glutathione 1,400 mg or placebo administered three times a week for 4 weeks.
  6. 06HumanRandomized controlled trialEfficacy outcome

    In Parkinson's disease, subsequent UPDRS ADL and motor worsening was 3.5 units greater after glutathione than placebo, without statistical significance.

    In plain wordsIn Parkinson's disease, subsequent daily activity and motor scores worsened 3.5 units more after glutathione than placebo, without statistical significance.

    Peptide
    Glutathione
    Outcome
    No significant changeUPDRS ADL and motor after treatment
    Study

    n: not reported in source

    Comparator
    Placebo
    Outcome group
    Exercise and physical function · Nervous system and cognition
    Studied dose
    1,400 mg three times a week · intravenous · 4 weeksAs given in this study (human).

    Measurements

    UPDRS ADL + motor worsening difference
    3.5 units
    glutathione versus placebo after treatment
    P value
    0.54
    after treatment

    Source sentences

    Summary
    Over the 4 weeks of study medication administration, UPDRS ADL + motor scores improved by a mean of 2.8 units more in the glutathione group (P = 0.32), and over the subsequent 8 weeks worsened by a mean of 3.5 units more in the glutathione group (P = 0.54).
    2 context sentences
    Summary · context
    This was a randomized, placebo-controlled, double-blind, pilot trial in subjects with PD whose motor symptoms were not adequately controlled with their current medication regimen.
    Summary · context
    Subjects were randomly assigned to receive intravenous glutathione 1,400 mg or placebo administered three times a week for 4 weeks.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Registered trials1

Trials this study reports on, or that list this study as a reference. Registry data from ClinicalTrials.gov.

1 trial · 1 completed · source ClinicalTrials.gov (opens in a new tab)

CompletedPhase 1NCT02324426

CNS Uptake of Intranasal Glutathione

University of Washingtonn = 15Dec 2014 to Mar 2015

Parkinson's Disease

Trial pageClinicalTrials.govUpdated 30 Apr 2015

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    14 Oct 2026, 05:02 UTC

    Study results updated

  2. Version 1

    14 Oct 2026, 01:46 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.